Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on proprietary formulation technologies to meet major medical needs. At the core of the company’s development activities is AmorphOX, a proprietary formulation technology used to improve, among other things, the bioavailability and stability of pharmaceuticals.
Vinge’s team consisted of Rikard Lindahl, Joel Magnusson, William Söder and Amanda Sandström.
